Factors influencing uptake of pharmacogenetic testing in a diverse patient population

Public Health Genomics

Volumn 13, Issue 1, 2009, Pages 48-54

  O'daniel, J ^a   Lucas, J ^a   Deverka, P ^a   Ermentrout, D ^a,b   Silvey, G ^b   Lobach, D F ^b   Haga, S B ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pharmacogenetic testing; Public attitudes; Side effects

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; ETHNICITY; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HEALTH INSURANCE; HUMAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; ETHNIC GROUPS; FEMALE; GENETIC TESTING; GENOTYPING TECHNIQUES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; YOUNG ADULT;

EID: 77951130342     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000217795     Document Type: Article

References (32)

1. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
2. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-2279.
3. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
4. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER: Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34: 1373-1379.
5. Bond CA, Raehl CL: Adverse drug reactions in United States hospitals. Pharmacotherapy 2006; 26: 601-608.
6. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19. (Pubitemid 38869995)
7. The Royal Society: Pharmacogenetics dialogue, 2005. Available at http://royalsociety. org/page.asp?id=3779.
8. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W: Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7: 49-59.
9. Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K: Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 2007; 8: 1511-1519.
10. Almarsdottir AB, Bjornsdottir I, Traulsen JM: A lay prescription for tailor-made drugs - focus group reflections on pharmacogenomics. Health Policy 2005; 71: 233-241.
11. Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL, Condit CM: Informed lay p for delivery of racially varied pharmacogenomics. Genet Med 2003; 5: 393-399.
12. Rothstein MA: Public attitudes about pharmacogenomics; in Rothstein MA (ed): Pharmacogenomics: Social, Ethical, and Clinical Dimensions. New Jersey, Wiley-Liss, 2003, pp 3-27.
13. Kinney AY, Choi YA, DeVellis B, Kobetz E, Millikan RC, Sandler RS: Interest in genetic testing among first-degree relatives of colorectal cancer patients. Am J Prev Med 2000; 18: 249-252. (Pubitemid 30155674)
14. Nordin K, Bjork J, Berglund G: Factors influencing intention to obtain a genetic test for a hereditary disease in an affected group and in the general public. Prev Med 2004; 39: 1107-1114.
15. Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C: Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med 2005; 20: 131-138.
16. Goodman LA: Simple models for the analysis of association in cross-classifications having ordered categories. J Am Stat Assoc 1979; 74: 537-552.
17. Tambor ES, Rimer BK, Strigo TS: Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997; 68: 43-49.
18. Sanderson SC, Wardle J, Jarvis MJ, Humphries SE: Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Prev Med 2004; 39: 458-464.
19. Tercyak KP, Peshkin BN, Wine LA, Walker LR: Interest of adolescents in genetic testing for nicotine addiction susceptibility. Prev Med 2006; 42: 60-65.
20. Hipps YG, Roberts JS, Farrer LA, Green RC: Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test 2003; 7: 39-44.
21. Lipkus IM, Iden D, Terrenoire J, Feaganes JR: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 533-539.
22. Kinney AY, Croyle RT, Dudley WN, Bailey CA, Pelias MK, Neuhausen SL: Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African- American kindred with a BRCA1 mutation. Prev Med 2001; 33: 543-551.
23. Kessler L, Collier A, Brewster K, Smith C, Weathers B, Wileyto EP, Halbert CH: Attitudes about genetic testing and genetic testing intentions in African-American women at increased risk for hereditary breast cancer. Genet Med 2005; 7: 230-238. (Pubitemid 40638068)
24. Satia JA, McRitchie S, Kupper LL, Halbert CH: Genetic testing for colon cancer among African-Americans in North Carolina. Prev Med 2006; 42: 51-59.
25. Lerman C, Hughes C, Benkendorf JL, Biesecker B, Kerner J, Willison J, Eads N, Hadley D, Lynch J: Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol Biomarkers Prev 1999; 8: 361-367.
26. Armstrong K, Micco E, Carney A, Stopfer J, Putt M: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 2005; 293: 1729-1736.
27. Halbert CH, Kessler L, Stopfer JE, Domchek S, Wileyto EP: Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Genet Med 2006; 8: 576-582.
28. Haga SB, Burke W: Pharmacogenetic testing: not as simple as it seems. Genet Med 2008; 10: 391-395.
29. Slaughter LM: The genetic information nondiscrimination act: why your personal genetics are still vulnerable to discrimination. Surg Clin North Am 2008; 88: 723-738.
30. Persky S, Kaphingst KA, Condit CM, Mc- Bride CM: Assessing hypothetical scenario methodology in genetic susceptibility testing analog studies: a quantitative review. Genet Med 2007; 9: 727-738.
31. Ropka ME, Wenzel J, Phillips EK, Siadaty M, Philbrick JT: Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev 2006; 15: 840-855.
32. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ: Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007; 7: 8.